9 Sep 2015
Paul Nash - Quealth Clinical Lead
Not quite – but we may at last have a drug that slows its progression.
It’s all over the news – and rightly so. The pharmaceutical company Eli Lilly have today announced that their dementia drug solanezumab could slow the rate at which Alzheimer’s progresses.
What you need to know:
it’s not a cure but it is the first drug ever to directly affect the progression of Alzheimer’s disease – no other treatment has ever been shown to do this
the initial trial ended unsuccessfully in 2012 but re-a...
Download Quealth to your phone today.